Great Point Partners LLC Savara Inc Transaction History

Great Point Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $1.57 Million - $7.73 Million	-660,366 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$6.71 - $8.6 $7.78 Million - $9.97 Million	-1,158,829 Reduced 63.7%	660,366 $4.87 Million
Q4 2018 Feb 15, 2019	SELL	$6.27 - $10.92 $2.66 Million - $4.63 Million	-423,889 Reduced 18.9%	1,819,195 $13.8 Million
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $11.2 Million - $13.8 Million	1,068,543 Added 90.98%	2,243,084 $25 Million
Q2 2018 Aug 14, 2018	BUY	$8.55 - $13.76 $2.67 Million - $4.3 Million	312,362 Added 36.23%	1,174,541 $13.3 Million
Q1 2018 May 14, 2018	SELL	$8.99 - $14.95 $65,815 - $109,448	-7,321 Reduced 0.84%	862,179 $0
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $7.18 Million - $14.6 Million	869,500	869,500 $12.9 Million

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $350M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.